Navigation Links
MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
Date:10/31/2013

MARIETTA, Ga., Oct. 31, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on November 14, 2013 at 9:00 a.m. EST at the Westin Grand Central Hotel.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 190,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Announces Record Third Quarter Results
2. MiMedx Reports On Meeting With FDA
3. MiMedx Responds To Misleading And Inaccurate Media Reports
4. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
5. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
6. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
7. MiMedx Announces Record Second Quarter Results
8. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
9. MiMedx To Exceed High End Of Second Quarter Guidance
10. MiMedx to Ring NASDAQ Stock Market Opening Bell
11. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... San Diego, CA (PRWEB) , ... January 24, ... ... pioneering the development of label-free graphene biosensor assays for fragment-based screening, ... 1317 at the 2017 Society for Laboratory Automation and Screening (SLAS) conference in ...
(Date:1/24/2017)... ... 2017 , ... Edward Buckler, Ph.D., a research geneticist focused ... of Sciences Prize in Food and Agriculture Sciences. He is being honored for ... of Sciences (NAS) Prize in Food and Agriculture Sciences was established in 2016 ...
(Date:1/24/2017)... , Jan. 23, 2017  Today, the Fisher ... they have funded an important study that could lead ... the onset of Alzheimer,s disease. This groundbreaking research was ... University, led by Nobel Laureate Dr. Paul Greengard ... Alzheimer,s disease. Fisher Center scientists have linked ...
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported ... to over 40 granted and pending patents. ... , The Company,s IP portfolio ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... hardware components needed to estimate the force and pressure applied to touch ...
(Date:12/7/2016)... --  Veridium , a leader in biometrics-based authentication ... James Stickland . Stickland, a seasoned financial ... served in senior executive roles for HSBC, JPMorgan ... a pipeline of venture capital and accelerating innovation ... as managing director of U.K.-based fintech firm Red ...
Breaking Biology News(10 mins):